ArticleInfection and immunity1994
T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy.
Article in Infection and immunity, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 147 citations in OpenAlex.
- TZ1391: a computationally designed circular mRNA multi-epitope vaccine candidate against Mycobacterium tuberculosis via TLR3 immunomodulation.BMC immunology · 2026Article
- Secreted proteins ofFrontiers in tuberculosis · 2026Review
- Bioinformatics Analysis and Immunogenicity Assessment of the Novel Multi-Stage DNA Vaccine W541 Against Mycobacterium Tuberculosis.Immunity, inflammation and disease · 2024Article
- Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development.NPJ vaccines · 2024Review
- Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice.NPJ vaccines · 2023Article
- The Induction of Antigen 85B-Specific CD8International journal of molecular sciences · 2023Article
- A novel multistage antigens ERA005f confer protection againstFrontiers in immunology · 2023Article
- Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022Review
- Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection againstVaccines · 2021Article
- Screening and evaluation of Mycobacterium tuberculosis diagnostic antigens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- MHC-restricted Ag85B-specific CD8European journal of immunology · 2019Article
- A Convenient Synthetic Method to Improve Immunogenicity ofVaccines · 2019Article
- Article
- Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity againstRSC advances · 2018Article
- Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection AgainstFrontiers in immunology · 2018Article
- Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans.The Journal of infectious diseases · 2016Article
- Adenylate kinase: a novel antigen for immunodiagnosis and subunit vaccine against tuberculosis.Journal of molecular medicine (Berlin, Germany) · 2016Article
- Structure-based Epitope Mapping of Mycobacterium tuberculosis Secretary Antigen MTC28.The Journal of biological chemistry · 2016Article
- The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis.Clinics in chest medicine · 2015Review
- Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.Mucosal immunology · 2015Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoproliferation and gamma interferon (IFN-gamma) secretion in response to 28 overlapping 20-mer synthetic peptides covering the complete sequence of the mature (295-amino-acid) 85A component of the major secreted, fibronectin-binding antigen 85 complex from Mycobacterium tuberculosis and Mycobacterium bovis BCG (MTAg85A) was examined by using peripheral blood mononuclear cell (PBMC) cultures from healthy tuberculin- and lepromin-positive volunteers and from patients with tuberculosis and leprosy. Peptide recognition was largely promiscuous, with a variety of human leukocyte antigen haplotypes reacting to the same peptides. PBMC from all tuberculin-positive subjects reacted to Ag85, and the majority proliferated in response to peptide 6 (amino acids 51 to 70), peptides 13, 14, and 15 (amino acids 121 to 160), or peptides 20 and 21 (amino acids 191 to 220). PBMC from tuberculosis patients demonstrated a variable reactivity to Ag85 and its peptides, and the strongest proliferation was observed against peptide 7 (amino acids 61 to 80). MTAg85A peptides were also recognized by PBMC from healthy lepromin-positive volunteers and paucibacillary leprosy patients (again in a promiscuous manner), but despite a 90% homology between the 85A proteins of M. leprae and M. tuberculosis, the peptides recognized were different. PBMC from lepromin-positive healthy contacts reacted against peptide 2 (amino acids 11 to 30), peptide 5 (amino acids 41 to 60), and peptides 25 and 26 (amino acids 241 to 270). PBMC from paucibacillary patients reacted preferentially against peptide 1 (amino acids 1 to 20) and peptide 5. Multibacillary patients were not reactive to Ag85 or the MT85A peptides. IFN-gamma production was generally detected simultaneously with positive lymphoproliferative responses, although peptide 1 mostly stimulated proliferation and peptides 27 and 28 mostly elicited an IFN-gamma response. In conclusion, regions 41 to 80 and 241 to 295 demonstrated powerful and promiscuous T-cell-stimulatory properties, resulting in proliferative responses and IFN-gamma secretion, respectively, in the majority of reactive subjects tested in this study. These results could be of value in the development of a subunit vaccine for tuberculosis and leprosy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.